- Home
- DNP vs KRYS Comparison
DNP vs KRYS Comparison
Compare DNP & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNP
- KRYS
- Stock Information
- Founded
- DNP 1986
- KRYS 2015
- Country
- DNP United States
- KRYS United States
- Employees
- DNP N/A
- KRYS N/A
- Industry
- DNP Investment Managers
- KRYS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DNP Finance
- KRYS Health Care
- Exchange
- DNP Nasdaq
- KRYS Nasdaq
- Market Cap
- DNP 3.6B
- KRYS 3.8B
- IPO Year
- DNP N/A
- KRYS 2017
- Fundamental
- Price
- DNP $9.79
- KRYS $139.44
- Analyst Decision
- DNP
- KRYS Strong Buy
- Analyst Count
- DNP 0
- KRYS 9
- Target Price
- DNP N/A
- KRYS $208.78
- AVG Volume (30 Days)
- DNP 494.5K
- KRYS 383.3K
- Earning Date
- DNP 01-01-0001
- KRYS 08-04-2025
- Dividend Yield
- DNP 7.98%
- KRYS N/A
- EPS Growth
- DNP N/A
- KRYS 109.01
- EPS
- DNP 1.56
- KRYS 4.16
- Revenue
- DNP $76,210,934.00
- KRYS $333,448,000.00
- Revenue This Year
- DNP N/A
- KRYS $44.05
- Revenue Next Year
- DNP N/A
- KRYS $46.15
- P/E Ratio
- DNP $6.26
- KRYS $33.49
- Revenue Growth
- DNP N/A
- KRYS 247.53
- 52 Week Low
- DNP $8.16
- KRYS $122.80
- 52 Week High
- DNP $10.04
- KRYS $219.34
- Technical
- Relative Strength Index (RSI)
- DNP 56.73
- KRYS 54.02
- Support Level
- DNP $9.72
- KRYS $135.86
- Resistance Level
- DNP $9.82
- KRYS $146.78
- Average True Range (ATR)
- DNP 0.08
- KRYS 5.45
- MACD
- DNP 0.00
- KRYS 1.12
- Stochastic Oscillator
- DNP 76.92
- KRYS 67.07
About DNP DNP Select Income Fund Inc.
DNP Select Income Fund Inc is a closed-ended investment management fund. The primary investment objectives of the fund are current income and long-term growth of income. Its secondary objective is capital appreciation. The Fund seeks to achieve its investment objectives by investing in the public utility industry.
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.